Notwithstanding encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from managed care entities. The companies are typically building barriers to reimbursement, like steep cost restrictions and PA that restrict user access. Analysts indicate that th